ELPEN Pharmaceutical Co., Inc.
🇬🇷Greece
- Country
- 🇬🇷Greece
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.elpen.gr
Clinical Trials
49
Active:5
Completed:30
Trial Phases
5 Phases
Phase 1:1
Phase 2:1
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (33.3%)Not Applicable
1 (16.7%)Phase 1
1 (16.7%)Phase 2
1 (16.7%)Phase 4
1 (16.7%)Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Not yet recruiting
- Conditions
- Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06949956
Real World Study in Greek Patients With BPH for Disease Control and QoL Under FDC Treatment With Solifenacin/Tamsulosin.
Recruiting
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06528613
- Locations
- 🇬🇷
Second Department of Urology, Sismanoglio Hospital, Athens, Greece., Athens, Greece
🇬🇷Department of Urology, Venizelio General Ηospital, Heraklion, Greece
🇬🇷Department of Urology, General Hospital of Messinia, Kalamata, Greece
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Completed
- Conditions
- Papillomavirus Infections
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT06399341
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷University General Hospital of Larissa, Larissa, Greece
🇬🇷University General Hospital of Patra, Patra, Greece
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Not yet recruiting
- Conditions
- COPD
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06170125
TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.
Recruiting
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06117722
- Locations
- 🇬🇷
ATTIKON University Hospital, Athens, Attica, Greece
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found